Research & clinical
Building the evidence base.
The Abron Walking Chair is a patent-pending concept in active development. Advancing it toward clinical use requires rigorous research, engineering validation, and regulatory review — and we're actively seeking partners to help build that foundation.
Where we are today.
The Abron Walking Chair is currently a patent-pending concept. No clinical trials have been conducted. No regulatory submissions have been filed. The information on this page reflects our development roadmap and the types of research and clinical partnerships we are seeking — not completed milestones.
Abron is not an FDA-cleared or FDA-approved medical device. No clinical efficacy or safety data exists at this stage. This page does not constitute a claim of medical benefit, regulatory approval, or guaranteed performance. All roadmap items are aspirational and subject to change based on engineering, testing, and regulatory outcomes.
Development roadmap
The path from concept to clinical use.
Bringing an adaptive mobility device to market requires a structured progression through engineering, preclinical validation, regulatory review, and clinical study. The following represents our intended development pathway.
Concept & IP
- Patent application filed (U.S. Application No. 19/571,170)
- Core system architecture defined
- Engineering partner identification underway
- Initial design documentation in development
Engineering & Prototype
- Mechanical and electrical system design
- Control system development and integration
- Bench-level prototype construction
- Initial functional testing
Preclinical Validation
- Biomechanical and load testing
- Safety and durability evaluation
- Human factors and usability assessment
- Design iteration based on test outcomes
Regulatory Pathway
- FDA regulatory strategy development (likely 510(k) or De Novo pathway)
- Quality management system implementation
- Pre-submission meeting with FDA
- Regulatory submission preparation
Clinical Study
- IRB-approved clinical study design
- Participant recruitment in collaboration with clinical partners
- Safety and efficacy data collection
- Publication and peer review
Research partnerships
Who we want to work with.
We are actively seeking research and clinical partners across several disciplines. If your organization has relevant expertise and interest in next-generation adaptive mobility, we'd like to hear from you.
Rehabilitation Medicine
Physiatrists, physical therapists, and occupational therapists who can contribute clinical insight into mobility needs, device usability, and real-world outcomes.
Biomedical Engineering
Academic and research labs with expertise in assistive technology, biomechanics, robotics, or human-machine interfaces.
Veterans & Military Medicine
VA medical centers, military rehabilitation programs, and veterans organizations serving individuals with mobility-related injuries.
Spinal Cord Injury Programs
SCI rehabilitation centers and research programs with experience in powered mobility and assistive technology evaluation.
Regulatory & Quality
Regulatory affairs consultants and quality management professionals with experience in FDA Class II medical device submissions.
Clinical Research Organizations
CROs and academic medical centers with experience designing and conducting IRB-approved assistive technology studies.
Regulatory context
Understanding the pathway.
Powered mobility devices are regulated by the FDA as medical devices. The Abron Walking Chair, if developed as intended, would likely require FDA clearance or approval before commercial distribution in the United States. We are in the early stages of developing our regulatory strategy.
Likely device classification
Powered wheelchairs and mobility aids are generally classified as Class II medical devices under FDA regulations. The specific classification and regulatory pathway for Abron will be determined in consultation with regulatory affairs professionals.
510(k) or De Novo
Depending on the final device design and intended use, the regulatory pathway may involve a 510(k) premarket notification (demonstrating substantial equivalence to a predicate device) or a De Novo request for novel device types.
International markets
Commercial distribution in the EU, Canada, Australia, and other markets would require separate regulatory submissions (CE marking, Health Canada, TGA, etc.). International regulatory strategy will be developed as the device matures.
Interested in a research partnership?
We welcome conversations with clinical researchers, academic institutions, rehabilitation programs, and regulatory professionals. Reach out to start a discussion.
Contact Us